CONCENTRATIONS |
9 Months Ended |
---|---|
Sep. 30, 2024 | |
CONCENTRATIONS | |
CONCENTRATIONS |
NOTE 16 - CONCENTRATIONS
Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
The Company’s revenues earned from sale of products and services for the three months ended September 30, 2023 included 87% from one customer of the Company’s total revenues.
The Company’s revenues earned from sale of products and services for the nine months ended September 30, 2024 included 89% from six customers of the Company’s total revenues.
The Company’s revenues earned from sale of products and services for the nine months ended September 30, 2023 included 74% from two customers of the Company’s total revenues.
At September 30, 2024, the Company has no accounts receivable. At December 31, 2023, one customer accounted for 100% of the Company’s total accounts receivable with an amount of $740. |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|